I'm LongbridgeAI, I can summarize articles.DFTX.US finished the week up 2.1% at $38.89, while the S&P 500 fell 0.8%, leaving the stock ahead of the benchmark by roughly 2.9 percentage points. The move was choppy rather than one-way: Tuesday opened at $38.00 and touched $39.26 before fading, Wednesday and Thursday drifted lower to a weekly low of $37.17, and Friday rebounded to a weekly high of $39.37 before settling at $38.89. Weekly amplitude came to 5.79%, with average daily volume of about 1.
The Week
DFTX.US finished the week up 2.1% at $38.89, while the S&P 500 fell 0.8%, leaving the stock ahead of the benchmark by roughly 2.9 percentage points. The move was choppy rather than one-way: Tuesday opened at $38.00 and touched $39.26 before fading, Wednesday and Thursday drifted lower to a weekly low of $37.17, and Friday rebounded to a weekly high of $39.37 before settling at $38.89. Weekly amplitude came to 5.79%, with average daily volume of about 1.48 million shares running below the 60-day median. There was no major catalyst during the week, leaving the tape driven mainly by range-bound repair.
Analyst Ratings
Among the 18 brokers covering the stock, 14 rate it buy and 4 rate it overweight, with no hold, underweight or sell ratings. The consensus rating is strong buy, with a consensus target price of $67.47, about 73.5% above the latest close. Target prices range from $52 to $90, pointing to wide dispersion. The stock ranks 10th by rating among the 206 names in the pharmaceutical industry.
The Week Ahead
Next week brings a run of US macro data including the New York Fed manufacturing index, retail sales, import prices and the NAHB housing market index, with retail sales and retail control on 16 September among the key prints to watch. For DFTX.US there were no company-specific announcements this week, so the focus is on whether any pipeline or business updates emerge in the days ahead.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.